DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Panobinostat
Panobinostat
Vorinostat—An Overview Aditya Kumar Bubna
FARYDAK (Panobinostat) RATIONALE for INCLUSION in PA PROGRAM
Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer
Management of Multiple Myeloma: the Changing Paradigm
In Patients with Metastatic Melanoma Nageatte Ibrahim1,2, Elizabeth I
Ninlaro, INN-Ixazomib
Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant
Broad-Spectrum HDAC Inhibitors Promote Autophagy Through FOXO Transcription Factors in Neuroblastoma
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
Treatment Options for Relapsed Or Refractory Multiple Myeloma
WO 2016/179306 Al 10 November 2016 (10.11.2016) P O P C T
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration- Resistant Prostate Cancer Anna C
Panobinostat: a Novel Mechanism of Action Shows Promise in Multiple Myeloma
Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19
FDA Listing of Established Pharmacologic Class Text Phrases January 2021
HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2 Tumors
SUPPLEMENTAL MATERIALS and METHODS Final
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Top View
Physiologically-Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) As a Victim and Perpetrator of Drug-Drug Interactions
Development of a Human in Vitro Blood–Brain Tumor Barrier Model Of
Table S1. Recent Registered Clinical Trials on Phenolic Compounds with Epigenetic Mechanisms in Different Cancers Alone and in Co-Treatment
Panobinostat (Farydak®) EOCCO POLICY
Emerging Drugs for Prostate Cancer
Panobinostat (Farydak®) Pronounced: “Pan‐Oh‐BIN‐Oh‐Stat”
Chemogenomic Screening Identifies the Hsp70 Co-Chaperone HDJ2 As
Pomalidomide and Dexamethasone Combination with Additional
NINLARO® (Ixazomib) Oral Capsule
HDACI): in Vitro and in Vivo Studies in Thyroid Cancer
The Synergistic Effect of DZ‑NEP, Panobinostat and Temozolomide Reduces Clonogenicity and Induces Apoptosis in Glioblastoma Cells
Leukemia Insights Spring 2011
Computationally Predicting Clinical Drug Combination Efficacy With
Recommendations for Patients with Relapsed/Refractory Disease1
Integration of Novel Agents Into the Care of Patients with Multiple Myeloma
State and Specialty Pharmacy Drug Reimbursement Rates
HDAC Inhibitors Elicit Metabolic Reprogramming by Targeting Super-Enhancers in Glioblastoma Models
FARYDAK Safely and Effectively